EA200702323A1 - Носитель для доставки в нервные клетки - Google Patents

Носитель для доставки в нервные клетки

Info

Publication number
EA200702323A1
EA200702323A1 EA200702323A EA200702323A EA200702323A1 EA 200702323 A1 EA200702323 A1 EA 200702323A1 EA 200702323 A EA200702323 A EA 200702323A EA 200702323 A EA200702323 A EA 200702323A EA 200702323 A1 EA200702323 A1 EA 200702323A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
nerve cells
native neurotoxin
delivery
carrier
Prior art date
Application number
EA200702323A
Other languages
English (en)
Other versions
EA012578B1 (ru
Inventor
Андреас Руммель
Таня Вайль
Александрс Гуйткайтс
Original Assignee
Токсоген Гмбх
Мерц Фарма Гмбх Энд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Токсоген Гмбх, Мерц Фарма Гмбх Энд Ко. Кгаа filed Critical Токсоген Гмбх
Publication of EA200702323A1 publication Critical patent/EA200702323A1/ru
Publication of EA012578B1 publication Critical patent/EA012578B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

Настоящее изобретение относится к транспортному белку, который может быть получен посредством модификации тяжелой цепи нейротоксинов, синтезируемых Clostridium botulinum, причем (1) белок специфически связывается с нервными клетками с большим или меньшим сродством, чем нативный нейротоксин; (2) белок обнаруживает повышенную или пониженную нейротоксичность по сравнению с нативным нейротоксином; при этом предпочтительно нейротоксичность определяют в анализе на препарате гемидиафрагмы; и/или (3) белок по сравнению с нативным нейротоксином обладает меньшим сродством к нейтрализующим антителам. Кроме того, приведены способы его получения и применения в косметических и фармацевтических композициях.
EA200702323A 2005-04-26 2006-04-26 Носитель для доставки в нервные клетки EA012578B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005019302A DE102005019302A1 (de) 2005-04-26 2005-04-26 Carrier zum Targeting von Nervenzellen
PCT/EP2006/003896 WO2006114308A2 (de) 2005-04-26 2006-04-26 Carrier zum targeting von nervenzellen

Publications (2)

Publication Number Publication Date
EA200702323A1 true EA200702323A1 (ru) 2008-04-28
EA012578B1 EA012578B1 (ru) 2009-10-30

Family

ID=36685707

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702323A EA012578B1 (ru) 2005-04-26 2006-04-26 Носитель для доставки в нервные клетки

Country Status (20)

Country Link
US (5) US8481040B2 (ru)
EP (4) EP3511338A3 (ru)
JP (1) JP2008538902A (ru)
KR (1) KR20080014754A (ru)
CN (1) CN101184770A (ru)
AU (1) AU2006239506A1 (ru)
BR (1) BRPI0610252A2 (ru)
CA (1) CA2606030A1 (ru)
DE (1) DE102005019302A1 (ru)
DK (1) DK3181578T3 (ru)
EA (1) EA012578B1 (ru)
ES (1) ES2723723T3 (ru)
HU (1) HUE044200T2 (ru)
IL (1) IL186508A0 (ru)
MX (1) MX2007013284A (ru)
PL (1) PL3181578T3 (ru)
PT (1) PT3181578T (ru)
TR (1) TR201905924T4 (ru)
WO (1) WO2006114308A2 (ru)
ZA (1) ZA200709166B (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
JP2008169166A (ja) * 2007-01-14 2008-07-24 Tokyo Univ Of Agriculture & Technology 糖結合性ポリペプチド、複合材料、及び薬剤送達システム
WO2008145359A1 (en) 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
KR101087017B1 (ko) * 2007-07-10 2011-12-09 (주)메디톡스 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물
WO2009015840A2 (en) * 2007-07-27 2009-02-05 Merz Pharma Gmbh & Co. Kgaa Polypeptide for targeting of neural cells
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
AU2008311820A1 (en) * 2007-10-17 2009-04-23 Ohmx Corporation Novel chemistry used in biosensors
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2664339A3 (en) 2008-03-17 2013-12-11 Universitätsklinikum Münster YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
AU2009286973B2 (en) 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
EP2161033B1 (en) 2008-09-09 2013-05-01 Susanne Dr. Grafe Botulinum toxin to introduce temporal infertiliy in a vertebrate (e.g. human)
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
BR112012028006A2 (pt) 2010-05-07 2016-08-02 Hoffmann La Roche método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
PL2761065T3 (pl) * 2011-09-29 2018-02-28 Cellsnap, Llc Kompozycje i sposoby do testów toksykogenności
KR102060355B1 (ko) * 2012-05-30 2019-12-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 가공된 보툴리눔 신경독소
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2015040215A1 (en) 2013-09-20 2015-03-26 Westfaelische Wilhelms-Universitaet Muenster Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
JP2017534598A (ja) * 2014-09-30 2017-11-24 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 神経系疾患を治療する標的療法のための汎用的なプラットフォーム
TWI669129B (zh) 2014-12-23 2019-08-21 德商梅茲製藥有限兩合公司 預填充式玻璃容器及其套組與使用
PL3242884T3 (pl) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Kationowe neurotoksyny
DK3274364T3 (da) 2015-03-26 2021-10-18 Harvard College Modificeret botulinumneurotoksin
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
AU2017277905B2 (en) * 2016-06-08 2022-04-14 Children's Medical Center Corporation Engineered Botulinum neurotoxins
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
PT3481852T (pt) * 2016-07-08 2023-02-22 Childrens Medical Center Nova neurotoxina botulínica e seus derivados
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
EP3746464A1 (en) * 2018-01-30 2020-12-09 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
WO2019243376A1 (en) 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
US20220357314A1 (en) 2018-09-28 2022-11-10 Ipsen Biopharm Limited Cell-based Clostridal Neurotoxin Assays
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
SE2050326A1 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
EP4313120A1 (en) 2021-03-30 2024-02-07 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
BR112023018473A2 (pt) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
CA3231083A1 (en) 2021-09-16 2023-03-23 Nicolae GRIGORE Modified bont/a for use in the treatment of cervical dystonia
WO2023047127A1 (en) 2021-09-23 2023-03-30 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
CA3234608A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan Inc Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9410871D0 (en) * 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6545126B1 (en) 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US7235521B1 (en) * 1999-05-17 2007-06-26 United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
US7132259B1 (en) * 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
US7368532B2 (en) * 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
PT1234043E (pt) * 1999-12-02 2004-07-30 Health Prot Agency Construcoes para a entrega de agentes terapeuticos a celulas neuronais
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
US7196189B2 (en) 2001-10-09 2007-03-27 Microbia, Inc. love variant regulator molecules
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
GB0216865D0 (en) 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
JP2006512090A (ja) * 2002-10-31 2006-04-13 ウイスコンシン アラムニ リサーチ ファンデーション ボツリヌス神経毒ｂ受容体およびその使用
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
GB2416089A (en) 2004-06-30 2006-01-11 Siemens Ag Sending cti messages in a communication system
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB2416692A (en) 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP1778279B1 (en) 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP1804832A4 (en) * 2004-10-04 2008-12-24 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES
US20070258992A1 (en) * 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
WO2006068794A2 (en) * 2004-11-22 2006-06-29 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US20070059326A1 (en) * 2004-12-02 2007-03-15 Michael Baldwin Escherichia coli-derived vaccine and therapy against botulism
AU2006225116B2 (en) * 2005-03-15 2012-04-19 Allergan, Inc. Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2008008082A2 (en) 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
WO2008105901A2 (en) * 2006-07-11 2008-09-04 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
US9803983B2 (en) 2010-12-03 2017-10-31 Qualcomm Incorporated Inertial sensor aided heading and positioning for GNSS vehicle navigation
KR102060355B1 (ko) * 2012-05-30 2019-12-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 가공된 보툴리눔 신경독소
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain

Also Published As

Publication number Publication date
US9650622B2 (en) 2017-05-16
US20130315888A1 (en) 2013-11-28
KR20080014754A (ko) 2008-02-14
EP3181578B1 (de) 2019-01-30
ZA200709166B (en) 2008-11-26
EP3511338A2 (de) 2019-07-17
BRPI0610252A2 (pt) 2010-06-08
US10266816B2 (en) 2019-04-23
AU2006239506A1 (en) 2006-11-02
EP3511338A3 (de) 2019-08-21
HUE044200T2 (hu) 2019-10-28
MX2007013284A (es) 2008-03-07
US9115350B2 (en) 2015-08-25
IL186508A0 (en) 2008-01-20
US8481040B2 (en) 2013-07-09
TR201905924T4 (tr) 2019-05-21
PL3181578T3 (pl) 2019-07-31
WO2006114308A3 (de) 2007-05-18
WO2006114308A8 (de) 2008-01-03
US10883096B2 (en) 2021-01-05
CN101184770A (zh) 2008-05-21
US20090311275A1 (en) 2009-12-17
WO2006114308A2 (de) 2006-11-02
DK3181578T3 (da) 2019-05-06
EP2345666A1 (de) 2011-07-20
US20150038401A1 (en) 2015-02-05
PT3181578T (pt) 2019-05-27
US20200024588A1 (en) 2020-01-23
EP1874803A2 (de) 2008-01-09
EA012578B1 (ru) 2009-10-30
US20170275607A1 (en) 2017-09-28
JP2008538902A (ja) 2008-11-13
DE102005019302A1 (de) 2006-11-16
CA2606030A1 (en) 2006-11-02
ES2723723T3 (es) 2019-08-30
EP3181578A1 (de) 2017-06-21

Similar Documents

Publication Publication Date Title
EA200702323A1 (ru) Носитель для доставки в нервные клетки
UA93359C2 (ru) Транспортный белок, который применяется для введения химических соединений k нервным клеткам
PE20171512A1 (es) Anticuerpos anti-fap
AU2017204797B2 (en) Antibodies with modified isoelectric points
PH12015501848A1 (en) Binding agents
UA97473C2 (ru) Выделенное антитело, которое связывается с her-3, и его применение
WO2012047427A3 (en) Antibodies for botulinum neurotoxins
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
EA200870264A1 (ru) Композиция антител
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
WO2007094754A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
EA201200861A1 (ru) Антагонисты pcsk9
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
MX347295B (es) Inmunoglobulinas portadoras y usos de las mismas.
WO2010014854A3 (en) Antibodies that neutralize botulinum neurotoxins
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2009015840A3 (en) Polypeptide for targeting of neural cells

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM